Tempus AI company profile
Company profile
Tempus AI has 3,800 employees and is headquartered in Chicago, United States.
With revenue of $1.3 billion in the fiscal year ended December 2025, Tempus AI operates its Tempus platform, which links clinician workflows with laboratory diagnostics, analytics and a repository of multimodal data. Its diagnostic offering includes next-generation sequencing tests, large-panel solid tumor and hematologic assays, pharmacogenomic testing for psychiatric conditions and genetic tests for inherited conditions. The group also licenses de-identified clinical, molecular and imaging datasets, offers clinical trial matching and develops software such as Lens, Next and Algos for life sciences research and diagnostics. Its customers include physicians and healthcare providers, and its strategic collaborations include AstraZeneca, GlaxoSmithKline, Merck, Recursion Pharmaceuticals and Blood Cancer United, the latter on a pediatric acute myeloid leukemia registry. Its operations are in the United States.
Revenue rose 83.4% from the prior year, and the company reported a net loss of $245.0 million for the fiscal year ended December 2025. It has 3,800 employees and is based in Chicago, Illinois. Founded in 2015, the company was formerly known as Tempus Labs, Inc. and adopted its current name in January 2023.
Company facts
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- United States
- Headquarters
- 600 West Chicago Avenue, 60654, Chicago
- Employees
- 3,800
- Chief executive
- Eric Lefkofsky
- Founded
- 2015
- Fiscal year
- January - December
- Listing
- TEM · NASDAQ
- Currency
- USD
- ISIN
- US88023B1035
- Website
- tempus.com
Tempus AI and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Tempus AITEM | United States | $11.81B | 3,800 | -18.5% | — |
| DoximityDOCS | United States | $5.85B | 880 | 27.1% | 45.5 |
| Veeva SystemsVEEV | United States | $48.46B | 7,928 | 29.9% | 49.1 |
| Pro MedicusPME | Australia | $14.19B | 153 | 74.9% | 79.4 |
| M32413 | Japan | $7.64B | 17,010 | 19.5% | 26.5 |
| XtalPi Holdings2228 | Hong Kong SAR China | $3B | 1,623 | -124.6% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
